This activity is expired and is no longer available for CME credit.


Optimizing Outcomes For Patients With Lung Cancer: Checkpoint Inhibitor Therapy in NSCLC, Patient Coaching, and Evaluation of Patient Reported Outcomes

Author(s)/Faculty: George R. Simon, MD, FACP, FCCP; Kelly Brassil, PhD, RN; Sarah Anderson, MSN, RN, AGPCNP-C, AOCNP; Yasir Y. Elamin, MD
Release Date: 8/17/2020Expiration Date: 8/16/2021
Credit Type: CME / CNE / CPE / AANPNumber of Credits: 0
Content Type: LectureProvider:
Lung cancer remains the leading cause of cancer death among both men and women. The American Cancer Society estimates that during 2020 within the United States, there will be approximately 228,820 new cases of lung cancer and about 135,720 deaths from this disease. More than half of patients die within 1 year of diagnosis, and 5-year survival for advanced disease is extremely limited. Utilization of recently approved immune-checkpoint inhibitors (ICIs) in treatment regimens for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has demonstrated clinical benefit and durable responses in some patients, providing a potential for enhanced long-term survival. In this educational activity, faculty discuss the use of checkpoint inhibitors in advanced lung cancer, emphasizing new data on the use of these regimens in the first-line setting of advanced disease. Experts also review appropriate use of ICIs in monotherapy and combination regimens, highlighting new indications for treating NSCLC and SCLC.